Skip to content

A multi-center, randomized, open, parallel-controlled clinical study evaluating the preventive effect of external application of mirabilite compared to conventional dressing on seroma after abdominal wall hernia repair

A multi-center, randomized, open, parallel-controlled clinical study evaluating the preventive effect of external application of mirabilite compared to conventional dressing on seroma after abdominal wall hernia repair

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000543
Enrollment
Unknown
Registered
2026-03-13
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abdominal hernia

Interventions

Experimental group:Wrap approximately 120g of refined mirabilite powder into a medicinal packet measuring about 10cm x 5cm using 5 layers of clean gauze, ensuring moderate tightness so as to prevent s
control group:Traditional compression bandaging. In the control group, a 500g sealed salt bag was routinely used to compress the incision for 6 to 12 hours postoperatively, followed by routine dressin

Sponsors

Beijing Anzhen Hospital Affiliated to Capital Medical University, Nanchong Hospital Nanchong Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The physical condition is assessed as ASA Class I-II, with no significant underlying heart or lung diseases, and patients in Class III are currently considered to have stable comorbidities for more than 3 months; (2) The patient is assessed to be able to tolerate laparoscopic surgery under general anesthesia; patients unable to tolerate general anesthesia are not suitable for open surgery; (3) The duration of surgery should not exceed 3 hours; (4) The patient is informed and signs the surgical consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with comorbidities that severely affect their activities, such as cardiac function class III or above, significant ascites, and lower limb mobility impairments, as well as those whose comorbidities interfere with their normal diet and work; (2) Patients with signs of peritonitis and comorbidities of severe liver and kidney organic diseases; (3) Patients with multiple malignant tumors;

Design outcomes

Primary

MeasureTime frame
sermon;Seroma fluid volume;

Secondary

MeasureTime frame
Incision healing condition;postoperative pain;

Countries

china

Contacts

Public ContactLuobinyu

Beijing Anzhen Hospital Affiliated to Capital Medical University, Nanchong Hospital Nanchong Central Hospital

luobinyu2014@126.com15908375554

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026